Readystate Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Readystate Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-67,602	Closed	-$145K	–	363
2025 Q2	$145K	Buy	+67,602	New	+$189K	﹤0.01%	567

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Readystate Asset Management's ADVM Position: Q3 2025 in Review

Readystate Asset Management sold out of Adverum Biotechnologies (ADVM) in Q3 2025, closing a stake of 67,602 shares — an estimated $145K sold.

Readystate Asset Management first reported a position in ADVM in Q2 2025 and held it in 1 quarter. The position peaked at $145K in Q2 2025. 50 funds tracked by Wall St. Rank hold ADVM as of Q3 2025.

Readystate Asset Management reported no remaining Adverum Biotechnologies position as of Q3 2025 after selling out during the quarter.
Readystate Asset Management sold 67,602 Adverum Biotechnologies shares in Q3 2025, an estimated $145K.
Readystate Asset Management first reported a position in Adverum Biotechnologies in Q2 2025 and held it in 1 quarter.
Readystate Asset Management's Adverum Biotechnologies position peaked at $145K in Q2 2025.
50 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.